by The colorectal cancer therapeutics market size is poised to grow by USD 18.25 billion by 2032 from USD 12.23 billion in 2023, exhibiting a CAGR of 4.55% during the forecast period 2023-2032.
Key Takeaways
- North America contributed the highest market share of 38% in 2022.
- Asia-Pacific is estimated to expand the fastest CAGR between 2023 and 2032.
- By therapy, the immunotherapy segment has held the largest market share of 49% in 2022.
- By therapy, the targeted therapy segment is anticipated to grow at a remarkable CAGR of 6.9% between 2023 and 2032.
- By cancer type, the colorectal adenocarcinoma segment has held the largest market share of 47% in 2022.
- By distribution channel, the hospital pharmacies segment has held the largest market share of 45% in 2022.
- By distribution channel, the retail pharmacies segment is anticipated to grow at a remarkable CAGR of 7.4% between 2023 and 2032.
Precedence Research has conducted a comprehensive market study that provides valuable insights into the performance of the market during the forecast period. The study identifies significant trends that are shaping the growth of the Colorectal cancer therapeutics market. In this recently published report, essential dynamics such as drivers, restraints, and opportunities are highlighted for both established market players and emerging participants involved in production and supply.
To begin with, the Colorectal cancer therapeutics Market report features an executive summary that offers a concise overview of the marketplace. It outlines the key players and industry categories expected to have an impact on the market in the coming years. The executive summary provides an unbiased summary of the market.
Get a Sample Report: https://www.precedenceresearch.com/sample/3643
Colorectal Cancer Therapeutics Market Scope
| Report Coverage | Details |
| Market Size in 2023 | USD 12.23 Billion |
| Market Size by 2032 | USD 18.25 Billion |
| Growth Rate from 2023 to 2032 | CAGR of 4.55% |
| Largest Market | North America |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | By Therapy, By Cancer Type, and By Distribution Channel |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Read More: AI in Life Science Analytics Market Poised to Exceed $5.10 Bn By 2032
The empirical study on the global Colorectal cancer therapeutics market primarily focuses on the drivers in subsequent sections. It demonstrates how changing demographics are projected to influence the supply and demand dynamics in the Colorectal cancer therapeutics Market. Our market report for the Colorectal cancer therapeutics market also delves into the significant rules and regulations that are likely to impact the future growth of this sector. Moreover, in order to comprehend the underlying demand factors, industry experts have provided insights into its fundamental origins.
Recent Developments
- November 2023: U.S. FDA (Food and Drug Administration) announced that it has approved Takeda’s oral targeted therapy for adults with metastatic colorectal cancer (mCRC), FRUZAQLA (fruquintinib). According to the company, FRUZAQLA is a chemotherapy-free treatment option and provide a considerable survival help to patients without much impacting their quality of life.
- August 2023: U.S. Food and Drug Administration (FDA) has approved Taiho Pharmaceutical Co., Ltd. and Taiho Oncology, Inc., LONSURF (trifluridine/tipiracil), to treat adult patients with metastatic colorectal cancer (mCRC) as a single agent or in combination with bevacizumab.
- June 2023: Enzene Biosciences has launched its cheaper drug for treatment of metastatic colorectal cancer, Bevacizumab. It is a biosimilar substitute to the more expensive Avastin.
Colorectal Cancer Therapeutics Market Players
- Bayer AG
- Bristol Myers Squibb
- Eli Lilly and Company
- Genentech, Inc.
- Ipsen Biopharmaceuticals, Inc.
- Merck Sharp & Dohme Corp.
- Pfizer Inc.
- Regeneron Pharmaceuticals, Inc.
- Sanofi
- Teva Pharmaceutical Industries Ltd.
- Taiho Pharmaceutical (Otsuka Pharmaceutical Co., Ltd.)
- Novartis AG
Data Sources and Methodology
To gather comprehensive insights on the Global Colorectal cancer therapeutics Market, we relied on a range of data sources and followed a well-defined methodology. Our approach involved interactions with industry experts and key stakeholders across the market’s value chain, including management organizations, processing organizations, and analytics service providers.
We followed a rigorous data analysis process to ensure the quality and credibility of our research. The gathered information was carefully evaluated, and relevant quantitative data was subjected to statistical analysis. By employing robust analytical techniques, we were able to derive meaningful insights and present a comprehensive overview of the Global Colorectal cancer therapeutics Market.
The most resonating, simple, genuine, and important causes because of which you must decide to buy the Colorectal cancer therapeutics market report exclusively from precedence research
- The research report has been meticulously crafted to provide comprehensive knowledge on essential marketing strategies and a holistic understanding of crucial marketing plans spanning the forecasted period from 2023 to 2032.
Key Features of the Report:
- Comprehensive Coverage: The report extensively encompasses a detailed explanation of highly effective analytical marketing methods applicable to companies across all industry sectors.
- Decision-Making Enhancement: It outlines a concise overview of the decision-making process while highlighting key techniques to enhance it, ensuring favorable business outcomes in the future.
- Articulated R&D Approach: The report presents a well-defined approach to conducting research and development (R&D) activities, enabling accurate data acquisition on current and future marketing conditions.
Market Segmentation:
By Therapy
- Targeted Therapy
- Immunotherapy
- Chemotherapy
- Others
By Cancer Type
- Colorectal Adenocarcinoma
- Gastrointestinal Carcinoid Tumors
- Others
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
Reasons to Consider Purchasing the Report:
- Enhance your market research capabilities by accessing this comprehensive and precise report on the global Colorectal cancer therapeutics market.
- Gain a thorough understanding of the overall market landscape and be prepared to overcome challenges while ensuring robust growth.
- Benefit from in-depth research and analysis of the latest trends shaping the global Colorectal cancer therapeutics market.
- Obtain detailed insights into evolving market trends, current and future technologies, and strategic approaches employed by key players in the global Colorectal cancer therapeutics market.
- Receive valuable recommendations and guidance for both new entrants and established players seeking further market expansion.
- Discover not only the cutting-edge technological advancements in the global Colorectal cancer therapeutics market but also the strategic plans of industry leaders.
Table of Content
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Colorectal Cancer Therapeutics Market
5.1. COVID-19 Landscape: Colorectal Cancer Therapeutics Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Colorectal Cancer Therapeutics Market, By Therapy
8.1. Colorectal Cancer Therapeutics Market, by Therapy, 2023-2032
8.1.1 Targeted Therapy
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Immunotherapy
8.1.2.1. Market Revenue and Forecast (2020-2032)
8.1.3. Chemotherapy
8.1.3.1. Market Revenue and Forecast (2020-2032)
8.1.4. Others
8.1.4.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Colorectal Cancer Therapeutics Market, By Cancer Type
9.1. Colorectal Cancer Therapeutics Market, by Cancer Type, 2023-2032
9.1.1. Colorectal Adenocarcinoma
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Gastrointestinal Carcinoid Tumors
9.1.2.1. Market Revenue and Forecast (2020-2032)
9.1.3. Others
9.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Colorectal Cancer Therapeutics Market, By Distribution Channel
10.1. Colorectal Cancer Therapeutics Market, by Distribution Channel, 2023-2032
10.1.1. Hospital Pharmacies
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Retail Pharmacies
10.1.2.1. Market Revenue and Forecast (2020-2032)
10.1.3. Online Pharmacies
10.1.3.1. Market Revenue and Forecast (2020-2032)
10.1.4. Others
10.1.4.1. Market Revenue and Forecast (2020-2032)
Chapter 11. Global Colorectal Cancer Therapeutics Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Therapy (2020-2032)
11.1.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.1.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Therapy (2020-2032)
11.1.4.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.1.4.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Therapy (2020-2032)
11.1.5.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.1.5.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Therapy (2020-2032)
11.2.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.2.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Therapy (2020-2032)
11.2.4.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.2.4.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Therapy (2020-2032)
11.2.5.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.2.5.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Therapy (2020-2032)
11.2.6.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.2.6.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Therapy (2020-2032)
11.2.7.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.2.7.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Therapy (2020-2032)
11.3.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.3.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Therapy (2020-2032)
11.3.4.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.3.4.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Therapy (2020-2032)
11.3.5.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.3.5.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Therapy (2020-2032)
11.3.6.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.3.6.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Therapy (2020-2032)
11.3.7.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.3.7.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Therapy (2020-2032)
11.4.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.4.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Therapy (2020-2032)
11.4.4.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.4.4.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Therapy (2020-2032)
11.4.5.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.4.5.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Therapy (2020-2032)
11.4.6.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.4.6.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Therapy (2020-2032)
11.4.7.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.4.7.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Therapy (2020-2032)
11.5.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.5.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Therapy (2020-2032)
11.5.4.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.5.4.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Therapy (2020-2032)
11.5.5.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.5.5.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
Chapter 12. Company Profiles
12.1. Bayer AG
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Bristol Myers Squibb
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Eli Lilly and Company
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Genentech, Inc.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Ipsen Biopharmaceuticals, Inc.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Merck Sharp & Dohme Corp.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Pfizer Inc.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Regeneron Pharmaceuticals, Inc.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Sanofi
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Teva Pharmaceutical Industries Ltd.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Unlocking Market Insights through Data Excellence
The “Precedence Statistics” flexible dashboard is a powerful tool that offers real-time news updates, economic and market forecasts, and customizable reports. It can be configured to support a wide range of analysis styles and strategic planning needs. This tool empowers users to stay informed and make data-driven decisions in various scenarios, making it a valuable asset for businesses and professionals looking to stay ahead in today’s dynamic and data-driven world.
Access our Premium Real Time Data Intelligence Tool, Visit: www.precedencestatistics.com
Precedence Statistics – Empowering Your Data Insights
Contact Us
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
